PortfoliosLab logo
EXEL vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EXEL and CRSP is 0.80, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Performance

EXEL vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

EXEL:

54.67%

CRSP:

122.57%

Max Drawdown

EXEL:

-9.21%

CRSP:

-11.86%

Current Drawdown

EXEL:

-9.21%

CRSP:

-5.32%

Fundamentals

Market Cap

EXEL:

$9.97B

CRSP:

$3.08B

EPS

EXEL:

$1.76

CRSP:

-$4.49

PEG Ratio

EXEL:

2.27

CRSP:

-0.21

PS Ratio

EXEL:

4.60

CRSP:

81.65

PB Ratio

EXEL:

4.44

CRSP:

1.68

Total Revenue (TTM)

EXEL:

$1.74B

CRSP:

$36.12M

Gross Profit (TTM)

EXEL:

$1.69B

CRSP:

-$93.67M

EBITDA (TTM)

EXEL:

$650.08M

CRSP:

-$311.55M

Returns By Period


EXEL

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

CRSP

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EXEL vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXEL
The Risk-Adjusted Performance Rank of EXEL is 9292
Overall Rank
The Sharpe Ratio Rank of EXEL is 9595
Sharpe Ratio Rank
The Sortino Ratio Rank of EXEL is 9292
Sortino Ratio Rank
The Omega Ratio Rank of EXEL is 9292
Omega Ratio Rank
The Calmar Ratio Rank of EXEL is 8585
Calmar Ratio Rank
The Martin Ratio Rank of EXEL is 9696
Martin Ratio Rank

CRSP
The Risk-Adjusted Performance Rank of CRSP is 2020
Overall Rank
The Sharpe Ratio Rank of CRSP is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 1717
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 2020
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 2424
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 1818
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EXEL vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

EXEL vs. CRSP - Dividend Comparison

Neither EXEL nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

EXEL vs. CRSP - Drawdown Comparison

The maximum EXEL drawdown since its inception was -9.21%, smaller than the maximum CRSP drawdown of -11.86%. Use the drawdown chart below to compare losses from any high point for EXEL and CRSP. For additional features, visit the drawdowns tool.


Loading data...

Volatility

EXEL vs. CRSP - Volatility Comparison


Loading data...

Financials

EXEL vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Exelixis, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B20212022202320242025
566.76M
0
(EXEL) Total Revenue
(CRSP) Total Revenue
Values in USD except per share items